evidoria

← Back to browse

Good practice Imported

MaRS Discovery District — research commercialisation hub

Canada · Toronto · See the Canada profile · See the Toronto profile

Evidence: Descriptive / self-reported Top 76% 57/100 · Ask Evidence Copilot about this practice

Toronto's 1.5-million-sq-ft innovation hub has worked to commercialise publicly funded research since 2000; MaRS reports ventures it supported raised $19B in capital and added 33,000+ jobs (2010-2021), though MaRS's own finances have come under independent scrutiny.

19 $ billion
Capital raised by supported ventures (2010-2021)
11.5 $ billion
Cumulative revenue generated by supported ventures (2010-2021)
29.6 $ billion
GDP contribution attributed to supported ventures (2010-2021)
33000 jobs (more than)
Jobs created by supported ventures (2010-2021)
40 % decline
MaRS own revenue decline (2019-2023)
MaRS Discovery District — research commercialisation hub

Details

Maturity
Established
Promoter
MaRS Discovery District (Province of Ontario, Government of Canada, University of Toronto and founding civic/academic leaders)
Period
2000-present
Keywords
Research commercialisation, technology transfer, health tech, cleantech

Context

MaRS Discovery District opened in Toronto in 2000 (its MaRS Centre building opened in 2005), founded by physician-researcher John Evans together with a group of civic, academic and business leaders, and modelled in part on Boston's Kendall Square biotech cluster. It occupies roughly 1.5 million square feet on Toronto's 'hospital row,' with a 2014 West Tower expansion and a 2023 waterfront building, and is funded mainly by the Province of Ontario and the Government of Canada alongside philanthropic and private capital.

Activities

MaRS Innovation, launched in 2008, pools intellectual-property rights from a consortium of 15 member institutions — including the University of Toronto, York University and several teaching hospitals — to provide centralised deal-structuring for commercialising publicly funded research. The Investment Accelerator Fund has invested roughly $80 million across more than 170 Ontario technology companies, and advisory services support over 1,200 startups. A 2024 pilot alongside University Health Network, Hospital for Sick Children and Sunnybrook Research Institute aims to speed medical-innovation commercialisation.

Results

MaRS' own impact reporting states that ventures it supported between 2010 and 2021 raised over $19 billion in capital, generated $11.5 billion in cumulative revenue, contributed $29.6 billion to Canada's GDP and created more than 33,000 jobs, with revenue growing at a 20.7% annualised rate. These figures are self-reported and have not been independently audited in the sources reviewed.

Conclusions

Independent reporting complicates the picture: The Globe and Mail reported that MaRS' own revenues fell 40% between 2019 and fiscal 2023 (down to $29.6 million), that the organisation posted losses in all five years reviewed, and that roughly two-thirds of its budget still depends on provincial and federal grants whose renewal is not guaranteed — prompting open debate about whether MaRS functions primarily as a real-estate operation or a genuine innovation engine.

Implementation

Indicative cost
Very high (> €5M) — 1.5 million sq ft campus across three phases (2005, 2014, 2023); ~$80 million Investment Accelerator Fund deployed across 170+ companies; MaRS' own annual revenue reported at $29.6 million (fiscal 2023, down 40% from 2019).
Time to results
Long (> 3 years) — Opened 2000 (MaRS Centre building 2005); West Tower expansion 2014; waterfront building 2023; MaRS Innovation IP-pooling launched 2008; impact figures reported for supported ventures 2010-2021.
Staffing & skills
Founded by physician-researcher John Evans with a group of civic, academic and business leaders, MaRS Innovation IP-pooling consortium spans 15 member institutions including the University of Toronto, York University and teaching hospitals

Conditions for success

  • Public funding backbone from the Province of Ontario and Government of Canada, supplemented by philanthropic and private capital
  • Centralised IP deal-structuring across a multi-institution consortium (MaRS Innovation) to avoid single-institution bottlenecks
  • Dedicated Investment Accelerator Fund (~$80m across 170+ companies) to bridge lab-to-market financing gaps

Common failure modes

  • The Globe and Mail reports a 40% revenue decline (2019-2023), losses in all five years reviewed, and roughly two-thirds budget dependency on government grants whose renewal is not guaranteed — a documented sustainability risk for the intermediary organisation itself, distinct from the ventures it supports

Where it fits

Governance type
non-profit public-private innovation hub
Scale
metropolitan (Toronto), multi-institution consortium
Income level
high-income (Canada)

Commonly funded by

National / regional programmes

Indicative funding routes for practices of this type — always check each programme's current calls and eligibility rules.

Do you run this practice? Claim it — verified implementers get a public contact pathway and can propose corrections.

Data sources

Where this practice's information was retrieved from, and when.

Attachments

Similar practices you may find useful